LInstitut National de la Sante et de la Recherche Medicale;L'Institut National de la Sante et de la Recherche Medicale
发明人:
Azria, David,Pelegrin, Andre,Larbouret, Christel,Gillies, Stephen D.
申请号：
AU2006332212
公开号：
AU2006332212B2
申请日:
2006.12.15
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody "trastuzumab" (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody "matuzumab" (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
